



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

hGPR91 antagonist 1

Cat. No.:	HY-126217		
CAS No.:	1314796-00-3		
Molecular Formula:	C ₃₁ H ₂₃ F ₄ N ₃ O		
Molecular Weight:	529.53		
Target:	Succinate Receptor 1		
Pathway:	GPCR/G Protein		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



SOLVENT & SOLUBILITY

In Vitro

DMSO : ≥ 125 mg/mL (236.06 mM)
 * "≥" means soluble, but saturation unknown.

	Solvent Concentration	Mass	1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM		1.8885 mL	9.4423 mL	18.8847 mL
	5 mM		0.3777 mL	1.8885 mL	3.7769 mL
	10 mM		0.1888 mL	0.9442 mL	1.8885 mL

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description	hGPR91 antagonist 1 (Compound 4c) is a potent and selective GPR91 antagonist with an IC ₅₀ of 7 nM for human GPR91 ^[1] .	
IC ₅₀ & Target	IC ₅₀ : 7 μM (HGPR91) ^[1]	
In Vivo	HGPR91 antagonist 1 (Compound 4c) leads to 59, 76% inhibition of ΔMAP at 2, 4 hours and has shown rat plasma protein binding 99%. HGPR91 antagonist 1 has engaged the target under the in vivo condition. HGPR91 antagonist 1 has clearance (CL) of 0.2 nmol/min/mg of RLM ^[1] .	
	MCE has not independently confirmed the accuracy of these methods. They are for reference only.	
	Animal Model:	Wistar rats ^[1]
	Dosage:	100 mg/kg

Administration:	I.p.; 2 and 4 hours
Result:	Led to 59 and 76% inhibition of Δ MAP at 2 and 4 hours.

REFERENCES

[1]. Bhuniya D, et al. Discovery of a potent and selective small molecule hGPR91 antagonist. Bioorg Med Chem Lett. 2011 Jun 15;21(12):3596-602.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA